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Summary: Ionised and total magnesium concentrations were determined in the serum of different groups of patients
suffering from renal or hepatic diseases. Ionised magnesium was measured by Microlyte 6 (KONE, Espoo, Finland)
and total magnesium by atomic absorption spectrometry.
In renal insufficiency ionised and total magnesium concentrations were almost equally increased. In proteinuria
with a normal glomerular filtration rate, "pseudohypomagnesaemia" was observed, i. e. decreased total magnesium
concentration in parallel with a decreased albumin concentration with no significant change in the concentration of
ionised magnesium.
Hypermagnesaemia occurred in liver diseases combined with renal insufficiency, whereas "pseudohypomagnesae-
mia" was most often found in the absence of renal failure. Also treatment with an aldosterone antagonist was
associated with a normal ionised magnesium concentration, but the total magnesium concentration was decreased;
when additional magnesium was administered, the total magnesium concentration approached a normal value, while
ionised magnesium slightly exceeded reference values. Only during cyclosporin treatment did both ionised and total
magnesium concentrations become lowered. However, the decrease of total magnesium exceeded that of ionised
magnesium due to concomitant hypoalbuminaemia with reduction of the protein-bound fraction. It is concluded
that especially low total magnesium concentrations should be investigated by measurement of ionised magnesium
to exclude "pseudohypomagnesaemia".
Introduction circumstances in which the concentration of active mag-
^ . ,. , . nesium ions is decreased or the less meaningful pseudo-
Renal as well as hepatic diseases may have an .mpact h esaemia be ted.
on magnesium balance. As long as only total magnesium
concentration could be determined (1-7), there were al-
ways some doubts as to whether alterations reflected
changes of the ionised (unbound) magnesium concentra- Materials and Methods
tion or the protein-bound concentration. As in the case ,* , - ι . ^ ι · · j Pat ientsof calcium, a decrease or an increase of the ionised mag-
nesium concentration may be considered as a "true" Renal diseases
change, whereas a decrease of the total magnesium con- L Group (RD ,): 21 patients (14 male) with renal diseascs
centration due to a reduction of protein-bound magne- (tab. I) and hypoalbuminaemia (albumin in the serum < 37 g/l) but
sium might be called a "pseudohypomagnesaemia". On "normal'* creatinine clearance (after adjustment to 1.73 m2 body
, ^ r j A, ^ , . A A. surface) were investigated (tab. 2). Patients suffering at the samethe other hand, the total magnesium concentration may time from gastro.intestinai diseaseSj hypo. or hyperthyroidism or
lie within the reference interval, while the ionised con- diabetes mellitus were excluded, as well as patients treated with
centration, reflecting the active magnesium ions, is low- cycJosporin (only two cases), cisplatin or calcium concentrations
, , -. ι v · j· ·* * - AL exceeding 2.60 mmol/1 serum,ered, because of complex binding, e. g. to citrate m the
event of massive transfusion of blood during liver trans- 2. Group (RD 2): 29 patients (19 male) with renal diseases
plantation (8). In this study, ionised and total magnesium <lab· ]>· hypoalbuminaemia and decreased creatinine clearance (ad-r . . , . · j · · justed to 1.73 m2 body surface) were investigated (tab. 2). They
concentrations m the serum were determined in patients were under Λί|οηβη1 with furoscmidc (mean dosage 103 mg/d;
suffering from liver or kidney diseases, to determine the range 40-250 mg/d). For exclusion criteria see RD 1.
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2. Group (LD 2): 20 patients (13 male) with hypoalbuminaemia
and increased creatinine concentration in the serum, treated with
furosemide (mean dosage 76 mg/d; range 20-240 mg/d) (tab. 4).
3. Group (LD 3): 11 patients (5 male) after orthotopic liver trans-
plantation with hypoalbuminaemia, treated with cyclosporin
(cyclosporin in serum: mean 115 g/l; range 59—161 g/l) (tab. 4).
4. Group (LD 4): 26 patients (17 male), with hypoalbuminaemia,
treated with furosemide (mean dosage 45 mg/d; range 20-80
mg/d) and spironolactone (mean dosage 115 mg/d; range 50-200
mg/d) (tab. 4).
5. Group (LD 5): 9 patients (4 male) with hypoalbuminaemia,
treated with spironolactone (mean dosage 83 mg/d; range 50-200
mg/d) (tab. 4).
6. Group (LD 6): 15 patients (9 male) with hypoalbuminaemia,
treated with furosemide (mean dosage 50 mg/d; range 20-120
mg/d), spironolactone (mean dosage 96 mg/d; range 50—200 mg/d)
and magnesium p. o. (Magnesium Verla™: mean dosage 112 mg/d;
range 80-240 mg/d) (tab. 4).
Tab. 2 Renal diseases
Property
1. Group (RD 1)
Mean Range



















































Tab. 3 Patients with diseases of the liver
Diagnosis No. of
patients
Chronic active hepatitis B 16
Chronic active hepatitis C 23
Chronic active hepatitis B and C 4
Alcohol toxic liver cirrhosis 28
Toxic liver cirrhosis (apart from alcohol toxic) 5
Autoimmune hepatitis 5
Primary biliary cirrhosis 9
Primary sclerotic cholangitis 6
arProteinase inhibitor deficiency 1
M. Mlson 2
Budd-Chiari syndrome 2
Liver cirrhosis (unknown origin) 9
Liver transplantation 11
Carcinoma of the liver/liver metastases 11
Liver diseases
The following groups with liver diseases were examined (for ex-
clusion criteria see RD 1):
1. Group (LD 1): 51 patients (31 male) with diseases of the liver
(tab. 3) and hypoalbuminaemia, but "normal" creatinine concentra-
tion in the serum (tab. 4).
The groups were compared with a group of 60 blood donors, who
were selected according to the guidelines (9) and matched for age
(mean ± standard deviation (years): 46.5 ± 12.2)) and sex (34
male, 26 female).
Sampling
Blood was obtained from the patients and the blood donors be-
tween 7 a. m. and 9.30 a. m. by venipuncture with Monovettes (Sar-
stedt, Nümbrecht). The serum was separated after centrifugation
(25 °C, 1200 g) and stored in a refrigerator (max. 5 days), if analy-
ses could not be performed at once.
Sample preparation
Serum for ionised magnesium measurement was adjusted to pH
7.40 ± 0.05 by bubbling CO2 gas prior to analysis.
Methods
Ionised magnesium
The concentration of ionised magnesium in the serum was deter-
mined by Microlyte 6 (KONE, Espoo, Finland). The ion-selective
electrode which was used for the measurement had a modified
ETrt 5220-containing PVC membrane. An Ag/AgCl-electrode was
used as a reference electrode. The ionised calcium concentration
was determined simultaneously, since this'is needed to account for
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the common calcium interference of the magnesium electrode. As
the degree of interference may change with time, the actual degree
at the time of measurement was determined by measurement of
standards (without protein) containing different concentrations of
calcium and magnesium just prior to the determination. Ionised
magnesium concentrations are reported for the actual pH of the
sample and for pH 7.40 after calculation by a built-in computer. In
this study ionised magnesium concentration is given after adjusting
to pH 7.4, to make comparison with the reference interval easier.
Other quantities
Ionised calcium, pH, ionised sodium and ionised potassium in se-
rum were determined simultaneously with ionised magnesium by
Microlyte 6 (KONE, Espoo, Finland).
Total magnesium in serum and urine was determined by atomic
absorption spectrometry (AAS 1100, Perkin-Elmer, Uberlingen), at
285.2 nm after addition of LaCl3.
Albumin concentration in serum was determined by immunochem-
istry (Array, Beckman Instr., M nchen).
Creatinine concentration in serum was measured enzymatically
(Hitachi 747, Boehringer Mannheim, Mannheim).
Total calcium was determined after reaction with cresolphthalein
complexone (Hitachi 747, Boehringer Mannheim, Mannheim).
Total protein in serum was measured bichromatically by the biuret
reaction (Hitachi 747, Boehringer Mannheim, Mannheim).
Cholesterol and triacylglycerol in serum were determined enzymat-
ically (Hitachi 747, Boehringer Mannheim, Mannheim).
Bilirubin was measured bichromatically after reaction with 2.5-
dichlorphenyldiazonium salt (Hitachi 747, Boehringer Mannheim,
Mannheim).
Enzymes (aspartate aminotransferase, alanine aminotransferase,
cholinesterase) were determined according to the standard pro-
cedures of the German Society for Clinical Chemistry.
Creatinine concentration in urine was measured by Jqffe's reaction
(Elan, Eppendorf, Hamburg).
Total protein in urine was determined with the biuret reaction after
precipitation with trichloroacetic acid and blank correction.
Quality assessment
Precision
Kontrollogen-L (lot 623136) (Behring, Frankfurt/M.), and Qualitrol
Precision (Merck, Darmstadt) were used for assessment of
precision. All measurements of the ionised magnesium concentra-
tions were performed in duplicates, which were accepted, if their
values differed by less than 2%.
Statistics
Data of the different groups were compared by analysis of covari-
ance and Scheffe's test (10). Adequate Gaussian distribution was




Two control sera were analysed on 10 consecutive days
in duplicate. The coefficient of variation for ionised
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Tab. 5 Precision within days
Specimen Number Mean Relative
of deter- value SD'> (CV)2)
minations (mmol/1) (%)
ionised Mg concentration
KontrollogenL 10 0.534 2.2
Qualitrol Precision 10 0.547 2.0
Ionised Ca concentration
KontrollogenL 10 1.18 1.8
Qualitrol Precision 10 1.30 1.5
H+ ion concentration
KontrollogenL 10 6.5 · 10~5 7.8
Qualitrol Precision 10 7.0 · 10"6 8.6
!) Standart deviation
2) Coefficient of variation
magnesium based on mean values was 2.2% and 2.0%
(tab. 5).
Accuracy
Reference method values were not yet available to test
accuracy. The following may be considered as indicators
of accuracy.
1. Magnesium concentration in ultrafiltrates exceeded
ionised magnesium concentration by 4.9% (2).
2. Reference values obtained by an indirect method, by
the same or a different ion-selective electrode were sim-
ilar (tab. 6).









































































The reference intervals for total and ionised magnesium
were calculated from data of 60 healthy blood donors
and include the range between the 2.5th and 97.5th per-
centile (tab. 6). There was no significant influence of
age or sex on the reference interval of ionised and total
magnesium nor on the pertinent ratio as proven by
analysis of covariance. The same held true for the
following groups of patients.
Renal diseases
Ionised and total magnesium concentrations in the se-
rum of patients suffering from renal diseases are pre-
sented in table 7.
In patients with proteinuria (RD 1) and decreased albu-
min concentration in the serum, the total magnesium
concentration was 9% lower (statistically significant)
than in the reference group, whereas the ionised magne-
sium concentration was almost identical (-1%, statistic-
ally not significant); therefore the percentage of ionised
magnesium was increased. Figure 1 indicates that total
magnesium is dependent on albumin concentration,
UC-ER: difference between magnesium concentration in superna^·
tant after ultracentrifugation (determined by AAS) and complexed












10 15 20 25 30
Albumin [g/1]
35 40
Fig. 1 Fraction of ionised Mg and albumin in renal diseases
(RD1)
Slope: -0.002 Intercept 0.83 Coefficient of correlation: -0.44
RD 1: Renal disease.
whereas the ionised magnesium concentration is not in-
fluenced.
In renal insufficiency (RD 2) both, jthe ionised and total
magnesium concentration in the serum were equally ele-
Külpmann et al.: Ionised magnesium in renal and hepatic diseases 261









Total Mg 0.80 (0.06) 0.73 (0.05) [-'] 0.93 (0.09) [+]
(mmol/1)
Ionised Mg 0.57 (0.04) 0.56 (0.04) 0.65 (0.05) [+]
(mmol/1)
Ionised Mg
— 0.71 (0.03) 0.77 (0.04) [+] 0.71 (0.05)
Total Mg
[ ] Statistically significant negative [—] or positive [+] deviation
as compared with the mean of the control group
!) Control: Reference group of healthy blood donors
RD 1: Renal disease; creatinine concentration in the serum within
reference interval









10 15 20 25 30
Albumin [g/1]
35 40
Fig. 2 Fraction of ionised Mg and albumin in renal diseases
(RD2)
Slope: -0.002 Intercept: 0.78 Coefficient of correlation: -0.35
RD 2: Renal insufficiency.
vated (4- 15.6% vs + 16.2%) (tab. 7) as compared with
the reference group, and the fraction of ionised magne-
sium was unchanged. Nevertheless, the dependency of
total magnesium on albumin concentration in the serum
was still obvious (fig. 2). Magnesium excretion in the
urine was below the reference interval (2.5—8.5
mmol/d) and lower than in the patients with proteinuria
(RD 1), but the mean fractional excretion (7.0% ± 3.9%
(standard deviation)) exceeded group RD 1 (3.5%
± 1.2% (standard deviation)).
Liver diseases
Ionised and total magnesium concentrations in the se-
rum of patients suffering from liver diseases are pre-
sented in table 8.
In group LD 1 with normal renal function but with hy-
poalbuminaemia, the total magnesium concentration was
decreased by 6.2% as compared with the reference in-
terval, and the ionised magnesium concentration was de-
creased by only 2.7% (statistically not significant).
Hence, the ionised magnesium fraction was elevated. It
may be concluded that total magnesium is correlated
with the albumin concentration (fig. 3), whereas ionised
magnesium is not significantly affected.
In liver diseases combined with renal insufficiency (and
therapy with furosemide), LD 2 results resembled RD 2:
the mean concentration of ionised and total magnesium
were increased similarly (17% vs 13.8%), and the
ionised magnesium fraction was not significantly
changed. Correlation of total magnesium and albumin
concentration may be supposed from figure 4.
In patients treated with cyclosporin (LD 3), the decrease
of total magnesium concentration exceeded the decrease
of ionised magnesium (—17.5% vs —11.3%), and the
fraction of ionised magnesium was significantly ele-
vated (7.0%). Its correlation with albumin is presented
in figure 5.
In cases of treatment with furosemide and spironolac-
tone (LD 4) only the total magnesium concentration was
significantly changed (-7.5%) and hence the fraction of
ionised magnesium was elevated (+ 5.6%). It was
poorly correlated with the albumin concentration (fig-
ure 6).
During therapy of 9 patients with spironolactone as the
only diuretic (LD 5), ionised magnesium was slightly
decreased (1.9%), but total magnesium was clearly
(8.8%) lowered (but statistically not significant with
only 9 patients), and the fraction of free magnesium was
significantly elevated. Because of the small number of
patients the correlation with albumin may be misleading
and is not shown.
In patients treated with diuretics and substituted with
magnesium (LD 6), ionised magnesium was not signifi-
cantly elevated, total magnesium not significantly low-
ered, and the fraction of ionised magnesium not signifi-
cantly increased but correlated with the albumin concen-
tration (fig. 7).
Discussion
Before starting the study the reliability of the measure-
ment of ionised magnesium was evaluated. According to
the guidelines (11), the pertinent coefficient of variation
should not exceed 2.1%. In fact 2.2% and 2.0% were
achieved. Accuracy could not be directly checked as no
appropriate control sera are available. But there was in-
direct evidence that determinations were accurate (see
results). Precision and accuracy of the other methods
was better than required by the guidelines (11) (data
not shown).
Blood samples from all individuals were taken between
7 a. m. and 9.30 a. m. to exclude any influence of pos-
sible circadian rhythms.
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3. Group (LD 3)
(n= 11)
0.66 (0.07) [-]
' f 0.50 (0.04) [-]
0.76 (0.04) [-f ]





[ ] Statistically significant negative [-] or positive [+] deviation LD 3: Orthotopic liver transplantation; treatment with cyclosporin
as compared with the mean of the control group
') Control: Reference group of healthy blood donors
LD 1: Liver disease
LD 2: Liver disease; creatinine concentration in the serum exceed-
ing the reference interval
LD 4: Liver disease; treatment with furosemide and spironolactone
LD 5: Liver disease; treatment with spironolactone
LD 6: Liver disease; treatment with furosemide, spironolactone
and magnesium salt p. o.
10 15 20 25 30
Albumin [g/1]
35 40
Fig. 3 Fraction of ionised Mg and albumin in liver diseases
(LD1)
Slope: -0.004 Intercept: 0.86 Coefficient of correlation: -0.36









10 15 20 25 30
Albumin [g/l]
35 40
Fig. 4 Fraction of ionised Mg and albumin in liver diseases
(LD2)
Slope: -0.003 Intercept: 0.81 Coefficient of correlation: -0.35
LD 2: Liver disease and renal insufficiency.
Renal diseases
In patients with "normal" serum creatinine concentration
and proteinuria (RD 1) it may be supposed that the total
magnesium concentration is lowered due to hypoalbu-
10 15 20 25 30
Albumin [g/1]
35 40
Fig. 5 Fraction of ionised Mg and albumin in liver diseases
(LD3)
Slope: -0.007 Intercept: 0.98 Coefficient of correlation: -0.77








10 15 20 25 30
Albumin (g/1]
35 40
Fig. 6 Fraction of ionised Mg and albumin in liver diseases
(LD4)
Slope: -0.002 Intercept: 0.81 Coefficient of correlation: -0.24
LD 4: Liver disease; treatment with furosemide and spironolactone.
minaemia ("pseudohypomagnesaemia"). Indeed, the
ionised magnesium concentration did not differ signif-
icantly from the normal concentration, and the ratio:
ionised magnesium/total magnesium was inversely






Fig. 7 Fraction of ionised Mg and albumin in liver diseases
(LD6)
Slope: -0.003 Intercept: 0.84 Coefficient of correlation: -0.36
LD 6: Liver disease; treatment with furosemide, spironolactone,
and magnesium salt p. o.
correlated with the albumin concentration. This ratio
minimises the impact of many other factors which simi-
larly influence total and ionised magnesium. Hence it
can be more clearly demonstrated that albumin concen-
tration only affects the total magnesium concentration,
i.e. total magnesium concentration was directly corre-
lated with the albumin concentration. Of course, the cor-
relation was not very strong, as ionised and total magne-
sium are more closely related.
In renal insufficiency, hypermagnesaemia was observed
due to a reduced glomerular filtratation rate of ultrafil-
terable magnesium, which was only partly counterbal-
anced by an increased fractional excretion rate. As io-
nised magnesium is the most important fraction of ultra-
filterable magnesium, its concentration also rose, as well
as the concentration of total magnesium which is in
equilibrium with ionised magnesium. Apart from the de-
cisive influence of renal function on the magnesium
concentration, the role of albumin was still demonstrable
(fig. 2), with the ionised magnesium fraction inversely
correlated with the albumin concentration.
Liver diseases
In liver diseases associated with hypoalbuminaemia and
normal renal function (LD 1), "pseudohypomagnesae-
mia" may be diagnosed for the same reasons as in the
RD 1-group. The changes were less distinct, as hypoal-
buminaemia was less pronounced. In cases of concomi-
tant renal insufficiency, changes resembled those in the
RD 2-group — with albumin still exerting an influence.
In patients treated with cyclosporin (LD 3) renal loss of
(ultrafilterable) magnesium was evident. Both the io-
nised and the total magnesium concentration were low-
ered. However, due to hypoalbuminaemia, the decrease
of total magnesium exceeded the decrease of ionised
magnesium and the fraction of ionised magnesium was
elevated.
During treatment with an aldosterone antagonist alone
or in combination with furosemide (LD 4, LD 5), a nor-
mal ionised magnesium concentration was maintained,
whereas the total magnesium concentration (affected by
the decreased albumin concentration) suggested magne-
sium deficiency. If treatment with an aldosterone antag-
onist was accompanied by magnesium administration,
the ionised magnesium concentration exceeded (not sig-
nificantly) the normal concentration; the total magne-
sium concentration was closer to normal, but it did not
attain a normal value on account of the reduced protein-
bound fraction.
It may be concluded that an increased concentration of
total magnesium is usually accompanied by an increase
of ionised magnesium, e. g. in renal insufficiency. A de-
creased total magnesium concentration is quite often the
result of "pseudohypomagnesaemia", which arises from
hypoalbuminaemia with a normal ionised magnesium
concentration. Among the patients investigated, a de-
creased ionised magnesium concentration was observed
only in patients receiving cyclosporin, i. e. these patients
suffered a true magnesium deficiency due to renal loss.
As "true" hypomagnesaemia (i.e. decreased ionised
magnesium concentration) was not observed in the more
severe stages of renal and hepatic diseases with distinct
hypoalbuminaemia, it may be assumed that the less seri-
ous stages are also not associated with "true" hypomag-
nesaemia. This means that "true" hypomagnesaemia is
not to be expected in renal diseases, whereas "true" hyp-
ermagnesaemia is likely to develop in cases of reduced
glomerular filtration rate.
In the same way severe liver diseases with or without
treatment with diuretics (furosemide and/or spironolac-
tone) usually do not lead to "true" hypomagnesaemia,
apart from cyclosporin treatment after orthotopic liver
transplantation. The influence of free fatty acids is obvi-
ously of minor importance. The investigated diseases are
not typically accompanied by a change in free fatty acid
concentration. A decrease of ionised magnesium con-
centration was not encountered, except in cyclosporin
treatment when it paralleled the total magnesium con-
centration. Therefore, it is recommended that decreased
total magnesium concentrations are further investigated
by measurement of the ionised magnesium concentra-
tion. Calculation of ionised magnesium from total mag-
nesium and albumin may be erroneous for the same
reasons that an analogous calculation of ionised calcium
is erroneous. Administration of magnesium should be
monitored by measurement of the ionised magnesium
concentration, which reflects the physiologically active
fraction of magnesium and assists in detecting inactiva-
tion by complexing agents. It may help to decide
whether patients may benefit from administration of
magnesium and increased magnesium concentrations.
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